Future Perspectives in Percutaneous Treatment of Tricuspid Regurgitation

12Citations
Citations of this article
23Readers
Mendeley users who have this article in their library.

Abstract

Tricuspid regurgitation (TR) has a not negligible prevalence and its severity is correlated with poorer outcomes. However, surgical options are rarely offered to these patients because of their high surgical risk. Given that medical therapy plays a limited role in the management of these patients, there is an increasing clinical need for transcatheter treatment options. Although, transcatheter tricuspid valve interventions (TTVIs) are still at an early stage, emerging data suggests their clinical effectiveness and safety, with preliminary results highlighting the potential benefits of transcatheter treatments over medical therapy. In this review, we highlight the challenges and future directions of current and emerging technologies dedicated to the treatment of TR along with an analysis of the next steps required in future clinical trials and studies dedicated to the treatment of the forgotten valve.

Cite

CITATION STYLE

APA

Mangieri, A., Pagnesi, M., Regazzoli, D., Laricchia, A., Ho, E., Goldberg, Y., … Latib, A. (2020, October 14). Future Perspectives in Percutaneous Treatment of Tricuspid Regurgitation. Frontiers in Cardiovascular Medicine. Frontiers Media S.A. https://doi.org/10.3389/fcvm.2020.581211

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free